US 12,226,373 B2
Treatment of fragile X syndrome with cannabidiol
Marcel Bonn-Miller, Lexington, NC (US); Nancy Tich, Saint Paul, MN (US); Donna Gutterman, Raleigh, NC (US); John Messenheimer, Moncure, NC (US); and Terri Sebree, Gladwyne, PA (US)
Assigned to Harmony Biosciences Management, inc., Plymouth Meeting, PA (US)
Filed by Harmony Biosciences Management, Inc., Plymouth Meeting, PA (US)
Filed on Aug. 30, 2023, as Appl. No. 18/458,727.
Application 18/458,727 is a continuation of application No. 17/895,008, filed on Aug. 24, 2022, granted, now 11,779,549, issued on Oct. 10, 2023.
Application 17/895,008 is a continuation of application No. 16/986,622, filed on Aug. 6, 2020, granted, now 11,458,110, issued on Oct. 4, 2022.
Application 16/986,622 is a continuation of application No. 16/594,317, filed on Oct. 7, 2019, granted, now 10,758,497, issued on Sep. 1, 2020.
Application 16/594,317 is a continuation of application No. 16/249,732, filed on Jan. 16, 2019, granted, now 10,471,022, issued on Nov. 12, 2019.
Application 16/249,732 is a continuation of application No. 16/144,632, filed on Sep. 27, 2018, granted, now 10,213,390, issued on Feb. 26, 2019.
Claims priority of provisional application 62/632,532, filed on Feb. 20, 2018.
Claims priority of provisional application 62/564,834, filed on Sep. 28, 2017.
Prior Publication US 2023/0414533 A1, Dec. 28, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/05 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 36/185 (2006.01); A61P 25/00 (2006.01)
CPC A61K 31/05 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 36/185 (2013.01); A61P 25/00 (2018.01)] 8 Claims
 
1. A method of reducing social avoidance behavior associated with a human suffering from Fragile X Syndrome comprising administering a therapeutically effective amount of synthetic cannabidiol to the human suffering from Fragile X Syndrome to effectively treat the Fragile X Syndrome in the human in need thereof.